Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial

Nimotuzumab (N) is a humanized anti‐epidermal growth factor receptor monoclonal antibody. This prospective, single‐armed, open label phase II study was conducted to evaluate the efficacy and safety of the combination of paclitaxel (T)/cisplatin (P) with nimotuzumab (N) as first‐line treatment in adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ming, Wang, Xicheng, Shen, Lin, Jia, Jun, Gong, Jifang, Li, Jie, Li, Jian, Li, Yan, Zhang, Xiaotian, Lu, Zhihao, Zhou, Jun, Zhang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832869/
https://www.ncbi.nlm.nih.gov/pubmed/26797530
http://dx.doi.org/10.1111/cas.12894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832869/
https://www.ncbi.nlm.nih.gov/pubmed/26797530
http://dx.doi.org/10.1111/cas.12894

Ejemplares similares